Associated Papers
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
Ai X et al.
European Journal of Cancer (oxford, England : 1990), 2026
Sustained Complete Response to Brigatinib in a Young Patient With ALK-Positive NSCLC Harboring I1171N Mutation Post-Alectinib Resistance.
Kapoor A et al.
Case Reports in Oncological Medicine, 2026
KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?
Krupa K et al.
Cancers, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.
Sakaguchi H et al.
Esmo Open, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
Waliany S et al.
Clinical Lung Cancer, 2025
Clinical Sequence Revealed the Prevalence and Biological Significance of Somatic Pathogenic Variants in Thoracic Cancer: Implications for Germline Status.
Fukushima T et al.
Clinical Lung Cancer, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Case Report: Metastatic colorectal cancer with ALK-CEP44 fusion and rapid resistance development.
Hofmann S et al.
Frontiers in Oncology, 2025
Case Report: Treatment response of SQSTM1-ALK fusion lung adenocarcinoma to multiple ALK inhibitors.
Gu J et al.
Frontiers in Pharmacology, 2025
Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1-ALK fusion: a case report and review.
Wang H et al.
Frontiers in Immunology, 2025
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ et al.
Cancer Discovery, 2024
Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
Tabe C et al.
Lung Cancer (amsterdam, Netherlands), 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD et al.
Esmo Open, 2024
An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.
Sharpe B et al.
Genes, Chromosomes & Cancer, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D et al.
Molecular Cancer, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
Ek T et al.
Cancer Research Communications, 2024
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.
Elhariri A et al.
Targeted Oncology, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
Itchins M et al.
Jto Clinical and Research Reports, 2024
Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer.
Xie Y et al.
Journal of Thoracic Disease, 2024
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
Wu L et al.
Journal of Translational Medicine, 2024
Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.
Orlic-Milacic M et al.
Database : the Journal of Biological Databases and Curation, 2024
Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
Inno A et al.
Clinical Lung Cancer, 2024
Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X et al.
Computers in Biology and Medicine, 2024
HIP1-ALK-Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report.
Ogimoto A et al.
Jto Clinical and Research Reports, 2024
A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review.
Cheng X et al.
Frontiers in Oncology, 2024
Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X et al.
Lung Cancer (amsterdam, Netherlands), 2023
Emden: A novel method integrating graph and transformer representations for predicting the effect of mutations on clinical drug response.
Liu Z et al.
Computers in Biology and Medicine, 2023
Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy.
Sasaki T et al.
Translational Lung Cancer Research, 2023
Deciphering the Shared and Specific Drug Resistance Mechanisms of Anaplastic Lymphoma Kinase via Binding Free Energy Computation.
Yu Y et al.
Research (washington, D.c.), 2023
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.
Kiełbowski K et al.
Frontiers in Pharmacology, 2023
Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM et al.
Genes, Chromosomes & Cancer, 2022
Characterization of driver mutations in Chinese non-small cell lung cancer patients using a novel targeted sequencing panel.
Zhao J et al.
Journal of Thoracic Disease, 2022
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C et al.
Cold Spring Harbor Molecular Case Studies, 2022
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X et al.
Investigational New Drugs, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A et al.
Nature Cancer, 2022
Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.
Nakagawa Y et al.
Thoracic Cancer, 2022
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Shen J et al.
Cellular Signalling, 2022
Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.
Pasau T et al.
Frontiers in Oncology, 2022
Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
Sampson J et al.
Embo Reports, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Christopoulos P et al.
Translational Lung Cancer Research, 2021
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021